DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,487 filers reported holding DANAHER CORPORATION in Q1 2020. The put-call ratio across all filers is 1.05 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $701,627 | +2.3% | 2,828 | -1.1% | 0.44% | -7.3% |
| Q2 2023 | $686,160 | +209.0% | 2,859 | +229.0% | 0.48% | +108.3% |
| Q1 2023 | $222,056 | +29117.9% | 869 | -69.7% | 0.23% | -57.5% |
| Q4 2022 | $760 | -99.9% | 2,864 | -0.2% | 0.54% | -13.6% |
| Q3 2022 | $741,000 | -0.7% | 2,870 | -2.5% | 0.63% | +10.2% |
| Q2 2022 | $746,000 | -14.2% | 2,944 | -0.6% | 0.57% | +13.8% |
| Q1 2022 | $869,000 | -11.3% | 2,963 | -0.6% | 0.50% | +9.4% |
| Q4 2021 | $980,000 | +7.8% | 2,980 | -0.2% | 0.46% | +38.2% |
| Q3 2021 | $909,000 | +54.3% | 2,985 | +35.9% | 0.33% | +68.4% |
| Q2 2021 | $589,000 | +19.5% | 2,196 | +0.2% | 0.20% | -35.9% |
| Q1 2021 | $493,000 | -33.8% | 2,191 | -34.7% | 0.31% | -89.1% |
| Q4 2020 | $745,000 | +2.1% | 3,354 | -1.0% | 2.80% | +602.0% |
| Q3 2020 | $730,000 | +15.0% | 3,388 | -5.7% | 0.40% | +6.1% |
| Q2 2020 | $635,000 | +27.8% | 3,593 | 0.0% | 0.38% | +74.9% |
| Q1 2020 | $497,000 | -14.0% | 3,593 | -4.5% | 0.22% | +4.9% |
| Q4 2019 | $578,000 | +7.6% | 3,763 | +1.2% | 0.20% | -31.0% |
| Q3 2019 | $537,000 | +3.1% | 3,718 | +2.0% | 0.30% | +44.9% |
| Q2 2019 | $521,000 | – | 3,644 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |